EtiraRx
PrivateLast Round
Accelerator
Apr 14, 2026
Total Funding Raised
$3.42M
Momentum Score
25 /100
Company Overview
EtiraRx is a biopharmaceutical company that develops novel cancer therapeutics to treat cancers by validating molecular drivers and evaluating mechanisms of therapy resistance.
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EtiraRx Comps
Public and private peers based on sector, stage, and business model.
EtiraRx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Apr 14, 2026 | ||||
| Seed | Oct 4, 2023 | ||||
| Grant | Aug 15, 2021 |
EtiraRx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| MassChallenge | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 14, 2026
Received funding from MassChallenge.
- Nov 10, 2025
Monthly visitors increased 62% MoM.
EtiraRx Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about EtiraRx's valuation, stock price, and market status.
Firmographic Details
HeadquartersDallas, Texas
Employee Range3
Year Founded2018
Last FundingApr 14, 2026
